4-氰基-5-甲基-4-(3-甲氧基苯基)己醛 | 103545-96-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 4-氰基-5-甲基-4-(3-甲氧基苯基)己醛
• 英文名称: 4-Cyano-5-methyl-4-(3-methoxyphenyl)hexanal
• 英文别名: 2-(3-Methoxyphenyl)-5-oxo-2-propan-2-ylpentanenitrile
• CAS: 103545-96-6
• 化学式: C₁₅H₁₉NO₂
• 分子量: 245.321
• InChiKey: YWPIBWKJRGHMPK-UHFFFAOYSA-N

物化性质

• 沸点：
  387.0±42.0 °C(Predicted)
• 密度：
  1.034±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  18
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.47
• 拓扑面积：
  50.1
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-氰基-5-甲基-4-(3-甲氧基苯基)己醛 在 sodium tetrahydroborate 、 甲酸 作用下， 以 水 为溶剂， 反应 3.5h， 生成 2-异丙基-5-{[3-(2-甲氧基-苯氧基)-丙基]-甲基-氨基}-2-(3-甲氧基-苯基)-戊腈
  参考文献：
  名称：

  Novel phenoxyalkylamine derivatives. II. Synthesis and Ca2+-antagonistic activities of .ALPHA.-alkyl-.ALPHA.-((phenoxypropylamino)propyl)-benzeneacetonitrile derivatives.

  摘要：

  含有不同取代基的α-烷基-α-[(苯氧丙胺)丙基]苯乙腈衍生物被合成，并评估了它们的Ca2+拮抗活性。在这些化合物中，具有在A环上带有3, 4, 5-(OMe)3基团、在四级碳原子上带有iso-Pr基团，以及在B环上带有m-OMe、3, 5-(OMe)2、3, 5-Me2或3, 4, 5-(OMe)3基团的N-Me衍生物被发现具有高于pA2=9的Ca2+拮抗活性。讨论了在A环、四级碳原子和B环上的取代效应。

  DOI：

  10.1248/cpb.36.373
• 作为产物：
  描述：

  3-甲氧基苯乙腈 在 草酸 、 sodium amide 作用下， 反应 4.5h， 生成 4-氰基-5-甲基-4-(3-甲氧基苯基)己醛
  参考文献：
  名称：

  Novel phenoxyalkylamine derivatives. II. Synthesis and Ca2+-antagonistic activities of .ALPHA.-alkyl-.ALPHA.-((phenoxypropylamino)propyl)-benzeneacetonitrile derivatives.

  摘要：

  含有不同取代基的α-烷基-α-[(苯氧丙胺)丙基]苯乙腈衍生物被合成，并评估了它们的Ca2+拮抗活性。在这些化合物中，具有在A环上带有3, 4, 5-(OMe)3基团、在四级碳原子上带有iso-Pr基团，以及在B环上带有m-OMe、3, 5-(OMe)2、3, 5-Me2或3, 4, 5-(OMe)3基团的N-Me衍生物被发现具有高于pA2=9的Ca2+拮抗活性。讨论了在A环、四级碳原子和B环上的取代效应。

  DOI：

  10.1248/cpb.36.373

文献信息

• Novel N-substituted alpha aminoacid amides as calcium channel modulators
  申请人：LILLY INDUSTRIES LIMITED

  公开号：EP0805147A1

  公开（公告）日：1997-11-05

  The compounds of formula I and derivatives thereof have been found to be active in tests that show modulation of voltage-dependent calcium channels, and are thus indicated for use in the treatment of diseases in which such modulation is beneficial, in particular diseases of the central nervous system.

  公式I及其衍生物的化合物已被发现在显示调节电压依赖性钙通道的测试中具有活性，因此适用于治疗对此类调节有益的疾病，特别是中枢神经系统疾病。
• Novel phenoxyalkylamine derivatives. V. Synthesis, .ALPHA.-blocking activity and quantitative structure-activity analysis of .ALPHA.-((phenoxyethylamino)propyl)-.ALPHA.-phenylacetonitrile derivatives.
  作者：KAZUYA MITANI、SHUNICHIRO SAKURAI、TOSHIHIRO SUZUKI、KOJI MORIKAWA、EIICHI KOSHINAKA、HIDEO KATO、YASUO ITO、TOSHIO FUJITA

  DOI：10.1248/cpb.36.4121

  日期：——

  α-[(Phenoxyethylamino) propyy]-α-phenylacetonitrile derivatives possessing various substituents on the benzene ring (A ring) at the phenylacetonitrile moiety, on the quaternary carbon atom and on the benzene ring (B ring) at the phenoxy moiety, and exhibiting various degrees of ablocking activity, were prepared. The variations in the activity were analyzed qualitatively as well as quantitatively by using physicochemical substituent parameters and a regression technique. The effect of substituents on the A ring was rationalized in terms of a parabolic function of their hydrophobic parameter. As regards substituents on the quaternary carbon atom, alkyl groups were desirable for high activity. The effects of substituents on the B ring were such that an optimum hydrophobic condition exists and that an alkoxy substituent at the o-position as well as smaller substituents at the m-and p-positions are favorable for high activity. The analysis for the combined series of analogs where substituents on the A and B rings are varied showed the existence of an optimum hydrophobicity for the whole molecule for the transport process of the molecule, besides above-mentioned various position-specific structural effects.

  合成了α-[(苯氧乙基氨基)丙基]-α-苯基乙腈衍生物，这些衍生物在苯乙腈部分的苯环（A环）上、在四面体碳原子上，以及在苯氧部分的苯环（B环）上，具有不同的取代基，并表现出各种程度的α-阻断活性。采用物理化学取代基参数及回归技术，对活性的变化进行了定性和定量分析。A环上取代基的影响根据其疏水参数的抛物线函数进行合理化。至于四面体碳原子上的取代基，烷基基团被认为是高活性的理想选择。B环上取代基的影响表明，存在一个最佳的疏水条件，并且在邻位的烷氧取代基以及在间位和对位的较小取代基有利于高活性。针对A环和B环取代基变化的综合系列类似物的分析显示，在分子的运输过程中，整个分子的最佳疏水性存在，此外也考虑了上述不同位置特异的结构效应。
• Novel phenoxyalkylamine derivatives. IV. Synthesis, Ca2+-antagonistic activity and quantitative structure-activity analysis of .ALPHA.-isopropyl-.ALPHA.-(3-(3-(3-methoxyphenoxy)propylamino)propyl)-.ALPHA.-phenylacetonitrile derivatives.
  作者：KAZUYA MITANI、SHUNICHIRO SAKURAI、TOSHIHIRO SUZUKI、KOJI MORIKAWA、EIICHI KOSHINAKA、HIDEO KATO、YASUO ITO、TOSHIO FUJITA

  DOI：10.1248/cpb.36.4103

  日期：——

  α-Isopropyl-α-[3-[3-(3-methoxyphenoxy) propylamino] propyl] -α-phenylacetonitrile derivatives containing various substituents on the benzene ring (A ring) at the phenylacetonitrile moiety were prepared, and their Ca2+-antagonistic activity was evaluated. Among these compounds, the N-Me derivatives with m-OMe, p-F, p-Cl, 3, 4-(OMe) 2 and 3, 5-(OMe) 2 substituents on the A ring were found to show higher Ca2+-antagonistic activity than verapamil. The effect of substituents on the A ring was examined quantitatively using physicochemical substituent parameters and regression analysis. The analysis showed that substituents with a π value close to zero are favorable to the activity and that optimum steric conditions exist for m-and p-substituents, corresponding to those of m-OMe and p-F or p-Cl. The analysis for the whole series of analogs where substituents on the A ring, the benzene ring (B ring) at the phenoxy moiety and the quaternary carbon atom are simultaneously varied suggested that there is an optimum molecular hydrophobicity, perhaps participating in the transport process to the site of action, besides position-specific steric and hydrophobic effects.

  制备了α-异丙基-α-[3-[3-(3-甲氧基苯氧基)丙氨基]丙基]-α-苯乙腈衍生物，并评估了它们的 Ca2+ 拮抗活性。在这些化合物中，发现在 A 环上具有 m-OMe、p-F、p-Cl、3，4-(OMe) 2 和 3，5-(OMe) 2 取代基的 N-Me 衍生物比维拉帕米具有更高的 Ca2+ 拮抗活性。利用物理化学取代基参数和回归分析对 A 环上取代基的影响进行了定量研究。分析结果表明，π值接近于零的取代基对活性有利，而 m 和 p 取代基存在最佳立体条件，相当于 m-OMe 和 p-F 或 p-Cl。对同时改变 A 环、苯氧基苯环（B 环）和季碳原子上的取代基的全系列类似物进行的分析表明，除了特定位置的立体效应和疏水效应外，还存在最佳的分子疏水性，这可能参与了向作用部位的迁移过程。
• N-substituted alpha aminoacid amides as calcium channel modulators
  申请人：ELI LILLY AND COMPANY LIMITED

  公开号：EP1041064A2

  公开（公告）日：2000-10-04

  A pharmaceutical compound having the formula in which R1 is alkyl, -SO2R14 where R14 is alkyl, optionally substituted aryl or optionally substituted heteroaryl, R2 is hydrogen, alkyl optionally substituted with one or more hydroxy or C1-4 alkoxy groups, optionally substituted aryl, optionally substituted heteroaryl, -OR15, -P(O)(OR15)(OR16) or -NR15R16 where R15 and R16 are each hydrogen or alkyl, or -SO2R17 where R17 is hydrogen, alkyl, optionally substituted aryl or optionally substituted heteroaryl, R3 is hydrogen, -CN, -CO2R18, -CONR18R19,-CH18≡CHR19, -C≡CR18, -OCH2CO.R18, -SO2R18, -CH2OR18, -CH2OCO.R18, -CH2NHCOR18, -CH2N(COR18)2, -CHO, -OR18, -CH2NR18R19, -CH2OR18, -CH=NR18 or -CH=N-OR18, where R18 and R19 are each hydrogen or alkyl, X is a bond or -SO2-, R4, R5, R6, R8, R9 and R10 are each hydrogen or alkyl, n is 1 to 4, A is -CH2- or -YCO- where Y is a bond, -O-, optionally substituted phenylene, -CH=CH-, or -NR20- where R20 is hydrogen or alkyl, R7 is the C-α substituent of an amino acid or an ester thereof, or R6 and R7 together form a C3-5 alkylene chain optionally substituted by C1-4 alkyl or hydroxyl, or a group of the formula -CH2-Z-CH2- where Z is -CO-, -S-, -SO- or -SO2-, or R7 and R8 together form a C3 to C5 alkylene chain optionally substituted by C1-4 alkyl or hydroxyl, B is -CON(R21)-, -CON(R21)N(R22)- or where -x=y- is -C(R22)=N-, -N=C(R22)- or -N=N-, where R21 is hydrogen, alkyl or -NR23R24 where R23 and R24 are each hydrogen or alkyl, and where R22 is hydrogen or alkyl, or R8 and R21 together form a C2-4 alkylene chain, m is 0 to 2, R11 is hydrogen or alkyl, R12 is hydrogen, alkyl, optionally substituted aryl, optionally substituted heteroaryl, -CN, -OH, -CO2R25, -CONR25R26, where R25 and R26 are each hydrogen or alkyl, and R13 is alkyl, optionally substituted aryl or optionally substituted heteroaryl, or R12 and R13 together form a C3-8 cycloalkyl group or C3-8 cycloalkyl fused to optionally substituted phenyl; or a salt or ester thereof.

  一种药物化合物，其化学式为 其中 R1是烷基、-SO2R14，其中R14是烷基、任选取代的芳基或任选取代的杂芳基、 R2 是氢、任选被一个或多个羟基或 C1-4 烷氧基取代的烷基、任选被取代的芳基、任选被取代的杂芳基、-OR15、 -P(O)(OR15)(OR16)或-NR15R16（其中 R15 和 R16 各为氢或烷基），或-SO2R17（其中 R17 为氢、烷基、任选取代的芳基或任选取代的杂芳基）、 R3 是氢、-CN、-CO2R18、-CONR18R19、-CH18≡CHR19、-C≡CR18、-OCH2CO.R18、-SO2R18、-CH2OR18、-CH2OCO.R18、-CH2NHCOR18、-CH2N(COR18)2、-CHO、-OR18、-CH2NR18R19、-CH2OR18、-CH=NR18 或 -CH=N-OR18，其中 R18 和 R19 各为氢或烷基、 X 是键或-SO2-、 R4、R5、R6、R8、R9 和 R10 各为氢或烷基、 n 为 1 至 4、 A 是-CH2-或-YCO-，其中 Y 是键、-O-、任选取代的亚苯基、-CH=CH-或-NR20-，其中 R20 是氢或烷基、 R7 是氨基酸或其酯的 C-α 取代基，或 R6 和 R7 共同形成任选被 C1-4 烷基或羟基取代的 C3-5 亚烷基链，或式 -CH2-Z-CH2- 的基团，其中 Z 是 -CO-、-S-、-SO- 或 -SO2-、 或 R7 和 R8 共同形成任选被 C1-4 烷基或羟基取代的 C3 至 C5 亚烷基链、 B 是-CON(R21)-、-CON(R21)N(R22)-或 其中-x=y-是-C(R22)=N-、 -N=C(R22)-或-N=N-，其中 R21 是氢、烷基或-NR23R24，其中 R23 和 R24 分别是氢或烷基，R22 是氢或烷基，或 R8 和 R21 共同形成 C2-4 亚烷基链、 m 为 0 至 2、 R11 是氢或烷基 R12 是氢、烷基、任选取代的芳基、任选取代的杂芳基、-CN、-OH、-CO2R25、-CONR25R26，其中 R25 和 R26 各自是氢或烷基，以及 R13 是烷基、任选取代的芳基或任选取代的杂芳基，或 R12 和 R13 共同形成 C3-8 环烷基或与任选取代的苯基融合的 C3-8 环烷基； 或其盐或酯。
• MITANI, KAZUYA;SAKURAI, SHUNICHIRO;SUZUKI, TOSHIHIRO;NORIKAWA, KOJI;KOSHI+, CHEM. AND PHARM. BULL., 36,(1988) N0, C. 4101-4120
  作者：MITANI, KAZUYA、SAKURAI, SHUNICHIRO、SUZUKI, TOSHIHIRO、NORIKAWA, KOJI、KOSHI+

  DOI：——

  日期：——